Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Cabozantinib (s)-Malate in Metastatic Renal Cell Carcinoma: NCT06377722 Clinical Landscape Report 2026
16 October 2026
NCT06377722 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tambiciclib in Diffuse large B-cell lymphoma refractory: NCT06375733 Clinical Landscape Report 2026
16 October 2026
NCT06375733 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
GC203 TIL(Shanghai Juncell Therapeutics) in Lung Cancer: NCT06375187 Clinical Landscape Report 2026
16 October 2026
NCT06375187 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT06375993 Clinical Landscape Report 2026
16 October 2026
NCT06375993 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Sitocabnagene loxiveluecel in Scleroderma, Systemic: NCT06377228 Clinical Landscape Report 2026
16 October 2026
NCT06377228 clinical landscape for Scleroderma, Systemic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Melanoma, Cutaneous Malignant: NCT06377111 Clinical Landscape Report 2026
16 October 2026
NCT06377111 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YTS-109 in Myositis: NCT06379646 Clinical Landscape Report 2026
16 October 2026
NCT06379646 clinical landscape for Myositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Letrozole in Endometrioid intraepithelial neoplasia: NCT06379113 Clinical Landscape Report 2026
16 October 2026
NCT06379113 clinical landscape for Endometrioid intraepithelial neoplasia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Cemiplimab-RWLC in Solid tumor: NCT06384807 Clinical Landscape Report 2026
16 October 2026
NCT06384807 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zilovertamab vedotin in Solid tumor: NCT06395103 Clinical Landscape Report 2026
16 October 2026
NCT06395103 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CHT-101 in Ovarian Cancer: NCT06383507 Clinical Landscape Report 2026
16 October 2026
NCT06383507 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lurbinectedin in Endometrial Carcinoma: NCT06385548 Clinical Landscape Report 2026
16 October 2026
NCT06385548 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.